@article{42c1f269c4be4a5ca3cd9640e68c8877,
title = "The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease",
abstract = "Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.",
keywords = "Alzheimer's disease, appropriate use recommendations, blood-based biomarkers, diagnosis, prognosis",
author = "Oskar Hansson and Edelmayer, {Rebecca M.} and Boxer, {Adam L.} and Carrillo, {Maria C.} and Mielke, {Michelle M.} and Rabinovici, {Gil D.} and Stephen Salloway and Reisa Sperling and Henrik Zetterberg and Teunissen, {Charlotte E.}",
note = "Funding Information: O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). C.E.T. has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly; performed contract research or received grants from AC‐Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of /Springer, , , and is editor of a Neuromethods book published by Springer. A.L.B. is supported by the NIH (U19AG063911, U54NS092089, R01AG038791, U01AG045390), Tau Research Consortium, Bluefield Project to Cure FTD, University of California Cures AD Program, Association for Frontotemporal Degeneration, CBD Solutions, Alzheimer's Drug Discovery Foundation, and the Alzheimer's Association. He receives research support from Biogen, Eisai, and Regeneron. He has served as a paid consultant for AGTC, Alector, Arkuda, Arvinas, AZTherapeutics, Denali, GSK, Humana, Oligomerix, Oscotec, Roche, Stealth, Third Rock, Transposon, Third Rock Ventures, TrueBinding, and Wave. R.A.S. is supported by NIH (P01AG036694; R01AG053798; R01AG054029; U24AG057437; R01AG061848; and R01AG063689), Alzheimer's Association, Fidelity, and GHR Foundation. She receives research support from Eli Lilly and Co., and Eisai. She has served as a paid consultant for AC Immune, Alynam, Genentech, Ionis, Janssen, NervGen, Oligomerix, Prothena, and Shioniogi. G.D.R. is supported by NIH (P30‐AG062422, R35 AG072362, U01‐AG057195, R21 P0545190), Alzheimer's Association (ZEN‐21‐848216), American College of Radiology, Rainwater Charitable Foundation, and the Alliance for Therapeutics in Neurodegeneration. He receives research support from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, and Genentech. He has served as a paid consultant for Eisai, Eli Lilly, Johnson & Johnson, and Roche. He is an Associate Editor for . R.M.E. is a full‐time employee of the Alzheimer's Association. M.C.C. is a full‐time employee of the Alzheimer's Association, and has a family member in the USC neuroscience graduate program. Medidact Neurologie Alzheimer Research and Therapy Neurology: Neuroimmunology & Neuroinflammation JAMA Neurology Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
month = dec,
doi = "https://doi.org/10.1002/alz.12756",
language = "English",
volume = "18",
pages = "2669--2686",
journal = "Alzheimer s & dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "12",
}